Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Receivables - Net (2018 - 2023)

Historic Receivables - Net for ImmunoTech (AIM) over the last 4 years, with Q4 2023 value amounting to $1.2 million.

  • ImmunoTech's Receivables - Net changed N/A to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that ImmunoTech reported Receivables - Net of $1.2 million as of Q4 2023.
  • In the past 5 years, ImmunoTech's Receivables - Net ranged from a high of $1.8 million in Q1 2023 and a low of $26000.0 during Q3 2020
  • For the 3-year period, ImmunoTech's Receivables - Net averaged around $311727.3, with its median value being $48000.0 (2023).
  • Examining YoY changes over the last 5 years, ImmunoTech's Receivables - Net showed a top increase of 24827.59% in 2019 and a maximum decrease of 8127.66% in 2019.
  • Over the past 3 years, ImmunoTech's Receivables - Net (Quarter) stood at $44000.0 in 2019, then plummeted by 40.91% to $26000.0 in 2020, then soared by 4453.85% to $1.2 million in 2023.
  • Its Receivables - Net stands at $1.2 million for Q4 2023, versus $48000.0 for Q3 2023 and $33000.0 for Q2 2023.